JPRN-jRCT1080224672
Completed
N/A
Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures (FYC02T)
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Eisai Co., Ltd.
- Enrollment
- 500
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Epilepsy participants from 12 to 17 years of age with:
- •1\) Partial seizures (with or without secondary generalized seizures)
- •2\) Primary generalized Tonic\-clonic seizures
Exclusion Criteria
- •Participants previously treated with Fycompa
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
N/A
Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adult Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic SeizuresJPRN-jRCT1080224671Eisai Co., Ltd.3,750
Unknown
N/A
Investigation of the clinical safety and efficacy of iguratimod in patients with rheumatoid arthritisRheumatoid ArthritisJPRN-jRCT1080222730Toyama Chemical Co., Ltd. (Current FUJIFILM Toyama Chemical Co., Ltd.)2,000
Unknown
N/A
Investigation of the clinical safety and efficacy of iguratimod in patients with rheumatoid arthritisRheumatoid ArthritisJPRN-jRCT1080222005Eisai Co., Ltd.2,000
Not Yet Recruiting
N/A
Investigation of the clinical safety and efficacy of favipiravir (Avigan tablets) in patients with novel or re-emerging influenza virus infectionsJPRN-jRCT1080223849FUJIFILM Toyama Chemical Co., Ltd. (Former Toyama Chemical Co., Ltd.)
Completed
Phase 2
Green Tea Ginger Flavor for Digestive WellbeingCTRI/2018/02/011860The Himalaya Drug Company40